SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease

Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were bett...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Bermudez, Luiz E., Kolonoski, Peter, Seitz, Lianne E., Petrofsky, Mary, Reynolds, Robert, Wu, Martin, Young, Lowell S.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC514788/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15328125/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.9.3556-3558.2004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares